Quinupristindalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: Efficacy and development of resistance

Scandinavian Journal of Infectious Diseases

Volumn 42, Issue 6-7, 2010, Pages 491-499

  Chong, Yong Pil ^a,b   Lee, Sang Oh ^a,b   Song, Eun Hee ^a,b   Lee, Eun Jung ^a,b   Jang, Eun Young ^a,b   Kim, Sung Han ^a,b   Choi, Sang Ho ^a,b   Kim, Mi Na ^a   Jeong, Jin Yong ^a,b   Woo, Jun Hee ^a,b   Kim, Yang Soo ^a,b  

^a University of Ulsan College of Medicine   (South Korea)

^b University of Ulsan   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; LINEZOLID; VANCOMYCIN; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE; QUINUPRISTIN-DALFOPRISTIN; VIRGINIAMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTEROCOCCUS FAECIUM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; AGED; CHI SQUARE DISTRIBUTION; DRUG EFFECT; GRAM POSITIVE INFECTION; MIDDLE AGED; PROGNOSIS; RISK FACTOR; STATISTICAL MODEL;

ACETAMIDES; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; CHI-SQUARE DISTRIBUTION; ENTEROCOCCUS FAECIUM; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OXAZOLIDINONES; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME; VANCOMYCIN RESISTANCE; VIRGINIAMYCIN;

EID: 77953257200     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365541003699623     Document Type: Article

References (27)

1. Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988;319:157-161
2. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-485
3. Montecalvo MA, Shay DK, Patel P, Tacsa L, Maloney SA, Jarvis WR, et al. Bloodstream infections with vancomycinresistant enterococci. Arch Intern Med 1996;156:1458-1462
4. Moellering RC, Linden PK, Reinhardt J, Blumberg EA, Bompart F, Talbot GH. The effi cacy and safety of quinupristin/ dalfopristin for the treatment of infections caused by vancomycin- resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother 1999;44:251-261
5. Linden PK. Treatment options for vancomycin-resistant enterococcal infections. Drugs 2002;62:425-441
6. Linden PK, Moellering RC Jr, Wood CA, Rehm SJ, Flaherty J, Bompart F, et al. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin Infect Dis 2001;33:1816-1823
7. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrugresistant, Gram-positive infections: experience from a compassionate- use program. Clin Infect Dis 2003;36:159-168
8. Erlandson KM, Sun J, Iwen PC, Rupp ME. Impact of the more-potent antibiotics quinupristin - dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia. Clin Infect Dis 2008;46:30-36
9. Raad I, Hachem R, Hanna H, Afi f C, Escalante C, Kantarjian H, et al. Prospective, randomized study comparing quinupristin - dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother 2004;53:646-649
10. Scheetz MH, Knechtel SA, Malczynski M, Postelnick MJ, Qi C. Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption. Antimicrob Agents Chemother 2008;52:2256-2259
11. Pai MP, Rodvold KA, Schreckenberger PC, Gonzales RD, Petrolatti JM, Quinn JP. Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2002;35:1269-1272
12. Hershberger E, Donabedian S, Konstantinou K, Zervos MJ. Quinupristin - dalfopristin resistance in Gram-positive bacteria: mechanism of resistance and epidemiology. Clin Infect Dis 2004;38:92-98
13. Oh WS, Ko KS, Song JH, Lee MY, Park S, Peck KR, et al. High rate of resistance to quinupristin - dalfopristin in Enterococcus faecium clinical isolates from Korea. Antimicrob Agents Chemother 2005;49:5176-5178
14. Noskin GA, Till M, Patterson BK, Clarke JT, Warren JR. High-level gentamicin resistance in Enterococcus faecalis bacteremia. J Infect Dis 1991;164:1212-1215
15. Mermel LA, Farr BM, Sherertz RJ, Raad II, O'Grady N, Harris JS, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001;32: 1249-1272
16. National Committee for Clinical and Laboratory Standards. Performance standards for antimicrobial susceptibility testing. M100-S12. Wayne, PA: NCCLS; 2002.
17. National Committee for Clinical and Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests. Eighth ed. Approved standard M2-A8. Wayne, PA: NCCLS; 2002.
18. Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996;23: 1234-1239
19. Lautenbach E, Schuster MG, Bilker WB, Brennan PJ. The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus. Clin Infect Dis 1998;27:1259-1265
20. Linden PK, Pasculle AW, McDevitt D, Kramer DJ. Effect of quinupristin/dalfopristin on the outcome of vancomycinresistant Enterococcus faecium bacteraemia: comparison with a control cohort. J Antimicrob Chemother 1997;39(Suppl A): 145-151
21. Dowzicky M, Talbot GH, Feger C, Prokocimer P, Etienne J, Leclercq R. Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid) during a worldwide clinical program. Diagn Microbiol Infect Dis 2000;37:57-62.
22. Weisblum B. Inducible resistance to macrolides, lincosamides and streptogramin type B antibiotics: the resistance phenotype, its biological diversity, and structural elements that regulate expression - a review. J Antimicrob Chemother 1985;16(Suppl A):63-90.
23. Bozdogan B, Leclercq R. Effects of genes encoding resistance to streptogramins A and B on the activity of quinupristin - dalfopristin against Enterococcus faecium. Antimicrob Agents Chemother 1999;43:2720-2725
24. Schmitz FJ, Sadurski R, Kray A, Boos M, Geisel R, Kohrer K, et al. Prevalence of macrolide-resistance genes in Staphylococcus aureus and Enterococcus faecium isolates from 24 European university hospitals. J Antimicrob Chemother 2000;45:891-894
25. Lopez F, Culebras E, Betriu C, Rodriguez-Avial I, Gomez M, Picazo JJ. Antimicrobial susceptibility and macrolide resistance genes in Enterococcus faecium with reduced susceptibility to quinupristin - dalfopristin: level of quinupristin - dalfopristin resistance is not dependent on erm (B) attenuator region sequence. Diagn Microbiol Infect Dis 2010;66:73-77
26. Falagas ME, Siempos, II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008;8:53-66.
27. Hachem RY, Hicks K, Huen A, Raad I. Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients. Clin Infect Dis 2003;37: e8 - 11.